Evidence map›Paper›PMID 27690294›Full record

Trial reportOncotarget2017

Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea.

Doo-Sik Kong, Do-Hyun Nam, Shin-Hyuk Kang, Jae Won Lee, Jong-Hee Chang, Jeong-Hoon Kim, Young-Jin Lim, Young-Cho Koh, Yong-Gu Chung, Jae-Min Kim and 1 more

Abstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 12 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 12 syntheses or guidelines pooled it.

  1. Pooled it
  2. A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Doo-Sik KongDepartment of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Do-Hyun NamDepartment of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Shin-Hyuk KangDepartment of Neurosurgery, College of Medicine, Korea University, Seoul, Korea.
Jae Won LeeDepartment of Statistics, Korea University, Seoul, Korea.
Jong-Hee ChangDepartment of Neurosurgery, Yonsei University College of Medicine, Seoul, Korea.
Jeong-Hoon KimDepartment of Neurosurgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Young-Jin LimDepartment of Neurosurgery, Kyunghee University Hospital, Seoul, Korea.
Young-Cho KohDepartment of Neurosurgery, Konkuk University Medical Center, Seoul, Korea.
Yong-Gu ChungDepartment of Neurosurgery, College of Medicine, Korea University, Seoul, Korea.
Jae-Min KimDepartment of Neurosurgery, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
Choong-Hyun KimDepartment of Neurosurgery, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAdoptive cell immunotherapy involves an ex vivo expansion of autologous cytokine-induced killer (CIK) cells before their reinfusion into the host. We evaluated the efficacy and safety of CIK cell immunotherapy with radiotherapy-temozolomide (TMZ) for the treatment of newly diagnosed glioblastomas. EXPERIMENTAL

designIn this multi-center, open-label, phase 3 study, we randomly assigned patients with newly diagnosed glioblastoma to receive CIK cell immunotherapy combined with standard TMZ chemoradiotherapy (CIK immunotherapy group) or standard TMZ chemoradiotherapy alone (control group). The efficacy endpoints were analyzed in the intention-to-treat set and in the per protocol set.

resultsBetween December 2008 and October 2012, a total of 180 patients were randomly assigned to the CIK immunotherapy (n = 91) or control group (n = 89). In the intention-to-treat analysis set, median PFS was 8.1 months (95% confidence interval (CI), 5.8 to 8.5 months) in the CIK immunotherapy group, as compared to 5.4 months (95% CI, 3.3 to 7.9 months) in the control group (one-sided log-rank, p = 0.0401). Overall survival did not differ significantly between two groups. Grade 3 or higher adverse events, health-related quality of life and performance status between two groups did not show a significant difference.

conclusionsThe addition of CIK cells immunotherapy to standard chemoradiotherapy with TMZ improved PFS. However, the CIK immunotherapy group did not show evidence of a beneficial effect on overall survival.

Indexed as

AdultAgedAntineoplastic Agents, AlkylatingBrain NeoplasmsChemoradiotherapyCombined Modality TherapyCytokine-Induced Killer CellsDacarbazineDisease-Free SurvivalFemaleGlioblastomaHumansMaleMiddle AgedRepublic of KoreaTemozolomideAntineoplastic Agents, AlkylatingDacarbazineTemozolomideautologous cytokine-induced killer cellglioblastomaimmunotherapy

Identifiers

PMID27690294
PMCPMC5351686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.